Persistence of influenza vaccine-induced antibody in lung transplant patients and healthy individuals beyond the season

Severson, Jill J.; Richards, Katelyn R.; Moran, John J.; Hayney, Mary S.

doi:10.4161/hv.21735

Cited by 14 publications

(12 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several reports have demonstrated that post‐vaccination antibody titers decline over the course of a year in both healthy children and adults . Otherwise, there are few studies concerning persistence of influenza vaccine‐induced antibodies in solid organ transplant patients . Moran et al .…”

Section: Discussionmentioning

confidence: 99%

Immunogenicity of inactivated seasonal influenza vaccine in adult and pediatric liver transplant recipients over two seasons

Suzuki

Torii

Kawada

et al. 2013

Microbiology and Immunology

View full text Add to dashboard Cite

Immunological responses to influenza vaccination administered to liver transplantation recipients are not fully elucidated. To compare inactivated influenza vaccine's immunogenicity between adult and pediatric recipients, 16 adult and 15 pediatric living donor liver transplantation recipients in the 2010-11 influenza season, and 53 adult and 21 pediatric recipients in the 2011-12 season, were investigated. Seroprotection rates (hemagglutinin-inhibition [HI] antibody titer 1:40) were 50-94% to all three antigens among adults and 27-80% among children in both seasons. Seroconversion rates (fourfold or more HI antibody rise) were 32-56% among adults and 13-67% among children in both seasons. No significant differences were observed between the two groups. In addition, 20/53 adult and 13/21 pediatric recipients received a vaccine containing identical antigens in both of these seasons. Geometric mean titer fold increases of all three antigens in adult recipients were significantly lower than those in recipients who had not received a preceding vaccination. In contrast, in pediatric recipients, there were no significant differences between the groups who had and had not received preceding vaccinations. The number of patients with rejection did not differ significantly between the two groups (0/53 vs. 1/21) in the 2011-12 season. The incidence of influenza after vaccination was significantly different between adult and pediatric recipients (0/16 vs. 5/15 in 2010-11 and 0/53 vs. 3/21 in 2011-12, respectively). Overall, there were no significant differences in antibody responses between adult and pediatric groups. Influenza infection was more frequent in pediatric recipients. Long-term response to preceding vaccinations appeared to be insufficient in both groups.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunogenicity of inactivated seasonal influenza vaccine in adult and pediatric liver transplant recipients over two seasons

Suzuki

Torii

Kawada

et al. 2013

Microbiology and Immunology

View full text Add to dashboard Cite

show abstract

“…Although Cox regression analysis addressed the complication of multiple exposures to the intervention, it created another difficult research question—how long should each patient be considered vaccinated following the vaccine administration? Based on previous studies that showed persistent antibody levels against influenza for 360 days post‐vaccination, we considered our patients to be vaccinated for 360 days after receiving the vaccine. However, another study showed seroprotection antibody levels greatly diminish after 180 days post‐vaccination .…”

Section: Discussionmentioning

confidence: 99%

“…However, this analysis is imperfect due to many patients receiving the influenza vaccine yearly, and these subsequent vaccinations potentially having an effect on the transplant outcomes we studied. In order to address these multiple exposures, we conducted a different analysis that showed persistent antibody levels against influenza for 360 days post-vaccination, 17,18 we considered our patients to be vaccinated for 360 days after receiving the vaccine. However, another study showed seroprotection antibody levels greatly diminish after 180 days postvaccination.…”

Section: Discussionmentioning

confidence: 99%

“…We considered all post‐transplant vaccines to determine vaccination status at any time during this period. Previous studies were conflicting on how long influenza vaccinations could possibly be effective for, which would dictate how long the vaccine could have immunologic effects on the transplant. With this debate, we performed separate analyses, one where a recipient was considered vaccinated for 360 days following the date of the post‐transplant vaccination, and another where a recipient was considered vaccinated for 180 days following the post‐transplant vaccination.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Effects of the influenza vaccine on pediatric kidney transplant outcomes

Camerino

Jackson

Chinnakotla

et al. 2019

Pediatric Transplantation

View full text Add to dashboard Cite

The influenza vaccine is critical for preventing influenza‐related complications in transplant patients. Previous studies demonstrated de novo donor‐specific antibody formation and rejection following the influenza vaccination. This risk has not been adequately assessed in the pediatric population. We performed a single‐center retrospective analysis of 187 unique pediatric kidney transplant recipients, transplanted from January 1, 2006, to December 31, 2015, assessing for an association of the influenza vaccination with various transplant outcomes. The influenza vaccine was received by 125 of 187 patients within the first year post‐transplant. Using log‐rank tests and Kaplan‐Meier curves, vaccinated patients had a significantly lower risk of mortality (P = 0.048). There were no differences in death‐censored graft survival (P = 0.253), graft survival (P = 0.098), or rejection (P = 0.195) between vaccinated and unvaccinated groups. To address the problem of multiple exposures for a yearly vaccine, Cox proportional hazards regression was utilized with post‐transplant vaccination status considered as a time‐dependent covariate; analyses were performed using both a 360‐ and 180‐day vaccination period following any post‐transplant influenza vaccination. In this model, being vaccinated did not result in a significant difference in mortality (HR 0.90 [0.16, 5.15], P = 0.91), death‐censored graft survival (HR 0.70 [0.31, 1.58], P = 0.39), graft survival (HR 0.69 [0.32, 1.49], P = 0.34), or rejection (HR 0.67 [0.37, 1.19], P = 0.17). Eight patients developed de novo donor‐specific antibodies following the first post‐transplant influenza vaccination; three then developed biopsy‐proven rejection. These results suggest influenza vaccination is safe in pediatric kidney transplant recipients, and larger prospective studies are required to conclusively confirm our findings.

show abstract

“…The WHO guide to vaccinations note that while pneumococcal polysaccharide vaccines induce an initial rise in antibody levels, these levels decline in older adults to pre‐vaccination levels after 4‐7 years . Many studies have shown that seasonal influenza antibodies may persist up to 4 years …”

Section: Discussionmentioning

confidence: 99%

Acquired hypogammaglobulinemia and pathogen‐specific antibody depletion after solid organ transplantation in human immunodeficiency virus infection: A brief report

Newman

Gregg

Estes

et al. 2019

Transplant Infectious Dis

View full text Add to dashboard Cite

Hypogammaglobulinemia (HGG) frequently occurs in recipients after types of (SOT). The incidence and significance of HGG in HIV+ recipients of SOT are just being explored. We reported that 12% of the recipients in the SOT in multi‐center HIV‐TR (HIV‐TR) Study developed moderate or severe HGG at 1 year. In LT recipients, this was associated with serious infections and death. We have now further characterized the decreased antibodies in HIV+ SOT recipients who developed HGG. We measured the levels of pathogen‐specific antibodies and poly‐specific self‐reactive antibodies (PSA) in relation to total IgG levels from serial serum samples for 20 HIV+ SOT recipients who developed moderate to severe HGG following SOT. Serum antibody levels to measles, tetanus toxoid, and HIV‐1 were determined by EIA. Levels of PSAs were determined by incubating control lymphocytes with patient serum, staining with anti‐human IgG Fab‐FITC, and analysis by flow cytometry. Levels of PSA were higher compared to healthy, HIV‐uninfected controls at pre‐transplant baseline and increased by weeks 12 and 26, but the changes were not significant. Likewise, anti‐HIV antibody levels remained unchanged over time. In contrast, antibody levels against measles and tetanus were significantly reduced from baseline by week 12, and did not return to baseline, even after 2 years. For HIV patients who develop moderate to severe HGG after transplant, the reduction in IgG levels is associated with a significant decrease in pathogen‐specific antibody titers, while PSA levels and anti‐HIV antibodies are unchanged. This may contribute to infectious complications and other clinical endpoints.

show abstract

Persistence of influenza vaccine-induced antibody in lung transplant patients and healthy individuals beyond the season

Cited by 14 publications

References 16 publications

Immunogenicity of inactivated seasonal influenza vaccine in adult and pediatric liver transplant recipients over two seasons

Immunogenicity of inactivated seasonal influenza vaccine in adult and pediatric liver transplant recipients over two seasons

Effects of the influenza vaccine on pediatric kidney transplant outcomes

Acquired hypogammaglobulinemia and pathogen‐specific antibody depletion after solid organ transplantation in human immunodeficiency virus infection: A brief report

Contact Info

Product

Resources

About